Article

Gender differences in alcohol treatment: An analysis of outcome from the COMBINE study

McLean Hospital, 115 Mill Street Belmont, MA 02478, USA.
Alcoholism Clinical and Experimental Research (Impact Factor: 3.31). 10/2010; 34(10):1803-12. DOI: 10.1111/j.1530-0277.2010.01267.x
Source: PubMed

ABSTRACT Relatively few studies have examined gender differences in the effectiveness of specific behavioral or pharmacologic treatment of alcohol dependence. The aim of this study is to assess whether there were gender differences in treatment outcomes for specific behavioral and medication treatments singly or in combination by conducting a secondary analysis of public access data from the national, multisite NIAAA-sponsored COMBINE study.
The COMBINE study investigated alcohol treatment among 8 groups of patients (378 women, 848 men) who received medical management (MM) with 16 weeks of placebo, naltrexone (100 mg/day), acamprosate (3 g/day), or their combination with or without a specialist-delivered combined behavioral intervention. We examined efficacy measures separately for men and women, followed by an overall analysis that included gender and its interaction with treatment condition in the analyses. These analyses were performed to confirm whether the findings reported in the parent trial were also relevant to women, and to more closely examine secondary outcome variables that were not analyzed previously for gender effects.
Compared to men, women reported a later age of onset of alcohol dependence by approximately 3 years, were significantly less likely to have had previous alcohol treatment, and drank fewer drinks per drinking day. Otherwise, there were no baseline gender differences in drinking measures. Outcome analyses of 2 primary (percent days abstinent and time to first heavy drinking day) and 2 secondary (good clinical response and percent heavy drinking days) drinking measures yielded the same overall pattern in each gender as that observed in the parent COMBINE study report. That is, only the naltrexone by behavioral intervention interaction reached or approached significance in women as well as in men. There was a naltrexone main effect that was significant in both men and women in reduction in alcohol craving scores with naltrexone-treated subjects reporting lower craving than placebo-treated subjects.
This gender-focused analysis found that alcohol-dependent women responded to naltrexone with COMBINE's Medical Management, similar to the alcohol-dependent men, on a wide range of outcome measures. These results suggest that clinicians can feel comfortable prescribing naltrexone for alcohol dependence in both men and women. In this study, it is also notable that fewer women than men reported receiving any alcohol treatment prior to entry into the COMBINE study. Of note, women tend to go to primary health care more frequently than to specialty substance abuse programs for treatment, and so the benefit we confirm for women of the naltrexone and MM combination has practical implications for treating alcohol-dependent women.

Download full-text

Full-text

Available from: Helen Pettinati, Aug 30, 2015
1 Follower
 · 
118 Views
  • Source
    • "irst suggested by a retrospective analysis of clinical trial data ( Kiefer et al . , 2005 ) . In support , a subsequent prospective study in nontreat - ment seeking heavy drinkers suggested that naltrexone decreased alcohol ' s stimulant effects in women only ( Tidey et al . , 2008 ) . In comparison , other clinical trials ( Baros et al . , 2008 ; Greenfield et al . , 2010 ) and laboratory studies ( David - son et al . , 1996 ; Drobes et al . , 2003 ) suggest that naltrexone is equally effective in both men and women , although most studies seem not to have tested for gender differences . Gender differences , the present study suggests , still warrant further investigation . The observation that women wit"
    [Show abstract] [Hide abstract]
    ABSTRACT: Alcohol-use disorders are thought to be heterogeneous in etiology, pathophysiology and response to treatment. One hypothesized contributor to this variability is the common A118G polymorphism of the µ-opioid receptor gene, OPRM1. This article critically evaluates the evidence that the A118G substitution affects subjective, behavioral and neurobiological responses to alcohol and the opioid receptor antagonist, naltrexone. Although screening of patients in a clinical setting remains premature, results suggest the A118G substitution may influence one etiological pathway to alcoholism, for which naltrexone pharmacotherapy is more effective.
    Pharmacogenomics 07/2012; 13(10):1161-72. DOI:10.2217/pgs.12.99 · 3.43 Impact Factor
  • Source
    • "Topiramate is an anticonvulsant with multiple pharmacological actions. Its use in substance use disorders including alcohol dependence has recently been reviewed (de Sousa, 2010; Johnson and Ait-Daoud, 2010; Shinn and Greenfield, 2010). Topiramate does not currently hold a licence for such use. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The British Association for Psychopharmacology guidelines for the treatment of substance abuse, harmful use, addiction and comorbidity with psychiatric disorders primarily focus on their pharmacological management. They are based explicitly on the available evidence and presented as recommendations to aid clinical decision making for practitioners alongside a detailed review of the evidence. A consensus meeting, involving experts in the treatment of these disorders, reviewed key areas and considered the strength of the evidence and clinical implications. The guidelines were drawn up after feedback from participants. The guidelines primarily cover the pharmacological management of withdrawal, short- and long-term substitution, maintenance of abstinence and prevention of complications, where appropriate, for substance abuse or harmful use or addiction as well management in pregnancy, comorbidity with psychiatric disorders and in younger and older people.
    Journal of Psychopharmacology 05/2012; 26(7):899-952. DOI:10.1177/0269881112444324 · 2.81 Impact Factor
  • Source
    • "irst suggested by a retrospective analysis of clinical trial data ( Kiefer et al . , 2005 ) . In support , a subsequent prospective study in nontreat - ment seeking heavy drinkers suggested that naltrexone decreased alcohol ' s stimulant effects in women only ( Tidey et al . , 2008 ) . In comparison , other clinical trials ( Baros et al . , 2008 ; Greenfield et al . , 2010 ) and laboratory studies ( David - son et al . , 1996 ; Drobes et al . , 2003 ) suggest that naltrexone is equally effective in both men and women , although most studies seem not to have tested for gender differences . Gender differences , the present study suggests , still warrant further investigation . The observation that women wit"
    [Show abstract] [Hide abstract]
    ABSTRACT: Few pharmacological treatments for alcohol dependence are available. Moreover, the best supported treatment, naltrexone hydrochloride, appears to work for only some. To investigate potential predictors of these differential responses, 40 social drinkers (20 women) were administered 6 days of treatment with naltrexone vs. placebo in a double-blind, counterbalanced, crossover design. At the end of each treatment period, participants received a single dose of their preferred alcoholic beverage followed by the opportunity to work for additional alcohol units using a progressive ratio (PR) breakpoint paradigm. All subjects but one were genotyped for the A118G polymorphism of the mu opioid receptor gene (OPRM1). Naltrexone decreased the ethanol-induced 'euphoria' to a priming dose of alcohol in two subgroups: (i) in women, and (ii) in subjects with the A118G polymorphism of the mu opioid receptor gene (OPRM1). Naltrexone did not decrease motivation to work for additional alcoholic beverages on the PR task regardless of gender or genotype. The results add to the evidence that naltrexone decreases positive subjective effects of alcohol, with preferential effects in distinct subgroups. Similar effects in heavier drinkers might decrease alcohol use.
    Alcoholism Clinical and Experimental Research 03/2011; 35(6):1134-41. DOI:10.1111/j.1530-0277.2011.01446.x · 3.31 Impact Factor
Show more